What Is a 503A Pharmacy? Key Facts & Regulations
503A pharmacies are one component of the healthcare system and may provide patient-specific compounded medications when clinically appropriate. They prepare medications based on individual patient prescriptions for home use or administration in a healthcare setting. This guide covers the key definitions, regulations, and business considerations for 503As.
What is a 503A Pharmacy?
Commercially available medications meet the needs of many patients; however, in certain clinical circumstances, prescribers may determine that a compounded preparation is appropriate.
In some cases, prescribers may order compounded medications when individual patient considerations—such as allergies, sensitivities, or dosage needs—are not addressed by commercially available products.
A 503A pharmacy, often referred to as "traditional" compounding pharmacy, prepares medication for each patient based on a prescription from a licensed provider to meet their unique needs.
Restore Health Consulting provides advisory services to compounding pharmacies related to regulatory compliance, quality systems, and operational readiness.
Schedule a free exploratory call with our experts today to get started.
503A Pharmacy Regulations and Standards
Patient Scenarios Requiring 503A Compounding
Some scenarios in which patients may need compounded medications include:
Allergies or sensitivities to dyes or ingredients
Difficulty swallowing standard tablets or capsules
Dosages not commercially available
Multi-drug combinations not sold commercially, such as pain creams
Compounding Quick Facts
Compounding in the U.S. dates back to the 1700s and has evolved with science and regulatory oversight.
2023 - 2024
According to 2023 - 2024 data from the Alliance for Pharmacy Compounding (APC), only 13% of U.S. compounding pharmacies were compounding-only; most were hybrid, providing both retail drugs and compounded medications.
In hybrid pharmacies, about 30% of prescriptions were compounded. Reported leading categories by volume are hormone replacement therapy (40%), veterinary (15%), and men’s health (12%). Around 40% of compounding pharmacies were licensed in multiple states, while 73% shipped less than 5% of compounds out of state.
Overall, in 2023 - 2024, roughly 7,500 pharmacies provided compounding services in the U.S.
2025 - 2026
APC’s new report: A Snapshot of Pharmacy Compounding in America 2025 - 2026 provides the latest data overview. The APC commissioned the Center for Business Research at the University of Mary Washington to conduct a demographic survey of over 16,500 pharmacy compounders across America, of which over 600 responded.
According to the APC survey data, GLP-1 preparations represented the third most commonly reported compounded therapy by volume. Hormone replacement therapy held the first place at 36% and veterinary stayed at a similar volume (14%). We also say dermatology compounds at 8% top men’s health, which dropped to 7%.
Looking specifically at compounded GLP-1s:
55% compounded semaglutide or tirzepatide preparations
The most common dosage for was sublingual (84%), followed by injectable (52%), and oral (8%)
33% of traditional pharmacies dispensed compounded GLP-1s sourced from a 503B outsourcing facility
24% expanded or moved to a larger facility to meet GLP-1 demand
They also found that median 503A compounding pharmacy in 2025 - 2026:
Dispenses 350 compounded medications/week
Serves 150 different prescribers of compounded medications
Works with 100 different compounding formulations/week
Has one location and 15 employees
Insurance coverage remains weak. While 25% of 503A compounding pharmacies accept some insurance for compounded medications, the circumstances in which insurance is accepted are limited. 61% do not accept insurance, and very few insurers cover compounded preparations at all.
Meanwhile, looking at the median 503B outsourcing facilities in 2025 - 2026:
66.7% distribute compounded non-sterile preparations to traditional pharmacies for patient-specific dispensing
75% distribute compounded sterile preparations to traditional pharmacies for patient-specific dispensing
Are All Compounding Pharmacies 503A?
No. There are two main types of compounding facilities: 503A pharmacies and 503B outsourcing facilities. 503Bs are FDA-registered and produce large volumes of sterile drugs, whereas 503As focus on patient-specific prescriptions.
How Is a 503A Pharmacy Different from a 503B Outsourcing Facility?
There are many key differences between 503A compounding pharmacies and 503B outsourcing facilities.
Regulatory framework: 503Bs follow federal cGMP; 503As comply with state regulations and USP standards.
Scale: 503Bs compound large batches; 503As produce individually prescribed medications.
Purpose: 503Bs supply healthcare providers at scale; 503As focus on personalized care.
Which is Better, 503A or 503B?
Neither is inherently “better.” Both 503As and 503Bs serve vital but distinct roles in the healthcare ecosystem. And both have unique advantages and challenges.
503As advance patient-specific care, while 503Bs provide large-scale access. Many healthcare systems use a hybrid approach, collaborating with both 503A and 503B facilities to meet diverse medication needs.
Read our full 503A vs. 503B breakdown here.
What are the Benefits of Using a 503A Pharmacy?
In 2026, 503A pharmacies continue to operate within a defined regulatory framework that allows for patient-specific compounding in circumstances where commercially available drug products may not meet prescriber-identified needs.
For patients: Compounded medications are tailored to unique therapeutic needs.
For providers: 503A pharmacies may support prescriber-directed, patient-specific compounding and pharmacist involvement consistent with applicable state law and USP standards. They help ensure continuity of care, support treatment adherence, expand therapeutic options beyond commercially available medications, and serve niche areas like pediatrics, specialty therapies, and veterinary medicine.
Regulatory Risk and Business Considerations
Compared to 503B outsourcing facilities, 503A pharmacies typically operate under different regulatory and operational constraints, which may affect cost structure, production scale, formulation flexibility, and market focus:
Lower startup and operational costs
Faster time to market
Flexibility to offer diverse formulations and dosing
Focus on local or regional markets
Niche opportunities with strong revenue potential
Limitations include production under patient-specific conditions only, restrictions on large batches of sterile compounds, and potential out-of-pocket costs for patients.
Read the full list of 503A benefits and disadvantages here.
503A Regulatory Framework
Key Regulations
503A pharmacies must:
Meet state pharmacy board regulations and federal laws (section 503A of FD&C Act)
Register with the Drug Enforcement Administration (DEA) if compounding and dispensing controlled substances
Comply with USP <795>, <797>, and <800> as applicable
Conduct facility certifications every six months
Assign Beyond Use Dates (BUDs) based on USP limits, supported by stability studies and/or general scientific literature reference
Limit sterile batch sizes to 250 units (in states adopting USP <797>)
They are statutorily exempt from FDA drug approval and cGMP requirements when operating in compliance with Section 503A conditions.
USP Standards
USP <795> Non-Sterile Compounding
USP <795> provides standards for pharmacies to ensure quality, safety, and consistency when compounding nonsterile medications. USP <795> covers facility cleanliness, personnel training, ingredient quality, process control, equipment, documentation, and setting accurate Beyond-Use Dates (BUDs). It applies to the compounding of nonsterile preparations such as oral liquids and suspensions, capsules and powders, topical creams, ointments, and gels, and suppositories and lozenges.
USP <797> Sterile Compounding
USP <797> provides guidance on preparing sterile compounded drugs (CSPs) like injectables, intravenous solutions, and ophthalmic preparations. USP <797> specifies requirements for facilities, personnel training, equipment, and aseptic techniques. It also provides guidance on categorizing risks (low, medium, high) and establishing beyond-use dates (BUDs) to limit contamination and ensure quality and safety in sterile compounding environments.
USP <800> Handling Hazardous Drugs In Healthcare Settings
USP <800> provides standards for safe handling of hazardous drugs to minimize the risk of exposure to healthcare personnel, patients and the environment. These guidelines cover all stages of handling, including receiving, storage, compounding, transport, administration, and the disposal of hazardous drugs.
Which Organization Regulates Traditional 503A Pharmacies?
“Traditional” 503A compounding pharmacies are regulated primarily by State Boards of Pharmacy. State Boards oversee licensure, routine inspections, and enforcement of USP compounding standards for patient-specific prescriptions. The FDA retains authority to inspect 503A pharmacies and enforce federal law; however, routine oversight and licensure are primarily conducted by State Boards of Pharmacy.
In practice, primary regulatory oversight of 503A pharmacies is generally exercised by State Boards of Pharmacy, with the FDA maintaining enforcement authority under federal law.
Does the FDA regulate 503A pharmacies?
The FDA may inspect and enforce federal law but does not typically oversee routine operations.
What is Section 503A of the FD&C Act?
Section 503A - Pharmacy Compounding of the Federal Food, Drug, and Cosmetic Act (FD&C Act) is the part of U.S. law that governs 503A pharmacy compounding. It allows pharmacies operating under Section 503A to compound patient-specific medications without FDA drug approval or compliance with current Good Manufacturing Practices (cGMP), provided they meet the statutory conditions and adhere to applicable USP compounding standards.
Quality standards for 503A compounding are established through USP chapters and are primarily enforced at the state level, rather than through FDA manufacturing regulations. Although administered by the FDA, Section 503A is statutory law, not an FDA guidance or regulation.
What is the 503A Compounding Rule?
The term “503A compounding rule” commonly refers to Section 503A of the FD&C Act.
More recently, the term may also refer to a rule proposed on March 20, 2024 by the US Food and Drug Administration (FDA) titled Drug Products or Categories of Drug Products that Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. While related, these are distinct regulatory concepts.
Proposed Rule on Sections 503A and 503B Compounding and DDC Lists
The proposed rule seeks to define the criteria used to determine which drug products or categories of drug products present demonstrable difficulties for compounding (DDC). Drug products placed on a DDC list may not be compounded under Section 503A or 503B.
Federal law requires the FDA to maintain:
A DDC list specific to 503A pharmacies, and
A separate DDC list for 503B outsourcing facilities.
The FDA’s proposal outlines three product categories that would be included on the initial DDC lists, all of which were reviewed by the Pharmacy Compounding Advisory Committee (PCAC) between 2016 and 2017:
1. Oral solid modified-release drug products that employ coated systems (MRCS)
2. Liposome drug products (LDPS)
3. Products produced using heat-melt extrusion (HME).
The agency also proposed six criteria it would consider when evaluating drugs for inclusion on a DDC list:
Complex formulation
Complex drug delivery mechanism
Complex dosage form
Bioavailability achievement complexity
Compounding process complexity
Physicochemical or analytical testing complexity
Regulatory Context and Industry Response
While the FDA has not identified specific currently marketed products affected by the proposal, the rule reflects increased regulatory attention to compounded drug product complexity. The new rule comes in the aftermath of increased interest in compounding semaglutide and related GLP-1 products, but it has been in the making for over 20 years—a period of tremendous changes in compounding regulation.
Industry groups, including the Alliance for Pharmacy Compounding (APC), have raised concerns that the proposed rule exceeds FDA authority by allowing entire categories of drugs to be added to DDC lists. They argue this approach could restrict access to entire classes of compounded therapies rather than addressing risks at the individual product level.
The APC has also raised concerns with the use of the terms “complex” and “complexity” without clear definitions or consistent application.
The public comment period closed on June 18, 2024. As of now, the FDA is reviewing submitted comments and has not finalized the rule.
The Takeaway
While the proposed DDC rule has not yet been finalized, it underscores the FDA’s continued focus on compounding oversight. 503A pharmacies, suppliers, and healthcare partners should monitor developments closely, particularly where product formulation complexity, dosage forms, or delivery mechanisms may introduce future regulatory risk.
Maximize Your 503A Pharmacy’s Potential
For organizations seeking support navigating 503A regulatory requirements, quality systems, or inspection readiness, Restore Health Consulting provides advisory services every day, across dozens of facilities. Contact us to learn how we can help.
Disclaimer:
The information provided on this website does not, and is not intended to, constitute clinical or legal advice; instead, all information, content, and materials available on this site are for general informational purposes only. Information on this website may not constitute the most up-to-date clinical, legal or other information. Readers of this website should contact their doctor or attorney to obtain advice with respect to any particular clinical or legal matter.